WHI Premarin Data Will Not Affect Bazedoxifene Phase III Studies, Wyeth Says
Executive Summary
The Women's Health Initiative hormone therapy safety findings will not affect the regulatory pathway for Wyeth's Phase III estrogen/SERM combination, VP-Investor Relations Justin Victoria said